HRP20151282T1 - Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina - Google Patents

Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina Download PDF

Info

Publication number
HRP20151282T1
HRP20151282T1 HRP20151282TT HRP20151282T HRP20151282T1 HR P20151282 T1 HRP20151282 T1 HR P20151282T1 HR P20151282T T HRP20151282T T HR P20151282TT HR P20151282 T HRP20151282 T HR P20151282T HR P20151282 T1 HRP20151282 T1 HR P20151282T1
Authority
HR
Croatia
Prior art keywords
groups
alkyl
group
alkyl group
disorder
Prior art date
Application number
HRP20151282TT
Other languages
English (en)
Inventor
Nobuaki Ito
Hirofumi Sasaki
Kuninori Tai
Tomoichi Shinohara
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20151282T1 publication Critical patent/HRP20151282T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)

Claims (11)

1. Heterociklički spoj, predstavljen formulom (1) ili njegova sol: [image] naznačen time, da m = 2, 1 = 1 i n =1; X -CH2-; R1 predstavlja vodik, C1-C6 alkilna skupina, hidroksi-C1-C6 alkilna skupina, zaštitna skupina odabrana od supstituiranog ili nesupstituiranog C1-C6 alkanoila, ftaloila, C1- C6 alkoksikarbonila, supstituiranog ili nesupstituiranog aralkilokskarbonila, 9- fluorenilmetioksikarbonila, nitrofenilsulfenila, aralkila i C1-C6 alkilsilil skupina ili tri- C1-C6 alkilsililoksi- C1-C6 alkilne skupine; R2 i R3, koji su isti ili različiti, svaki neovisno predstavljaju vodik ili C1-C6 alkilnu skupinu; ili R2 i R3 su vezani tako da tvore ciklo-C3-C8 alkilnu skupinu; a R4 predstavlja bilo koji od (1) fenilne skupine, (2) indolil skupine, (3) benzotienil skupine, (4) naftil skupine, (5) benzofuril skupine, (6) kinolil skupine, (7) izokinolil skupine, (8) piridil skupine, (9) tienil skupine, (10) dihidrobenzoksazinil skupine, (11) dihidrobenzodioksinil skupine, (12) dihidrokinolil skupine, (13) kromanil skupine, (14) kinoksalinil skupine, (15) dihidroindenil skupine, (16) dihidrobenzofuril skupine, (17) benzodioksolil skupine, (18) indazolil skupine, (19) benzotiazolil skupine, (20) indolinil skupine, (21) tienopiridilil skupine, (22) tetrahidrobenzazepinil skupine, (23) tetrahidrobenzodiazepinil skupine, (24) dihidrobenzodioksepinil skupine, (25) fluorenil skupine, (26) piridazinil skupine, (27) tetrahidrokinolil skupine, (28) karbazolil skupine, (29) fenantril skupine, (30) dihidroacenaftilenil skupine, (31) pirolopiridil skupine, (32) antril skupine, (33) benzodioksinil skupine, (34) pirolidinil skupine, (35) pirazolil skupine, (36) oksadiazolil skupine, (37) pirimidinil skupine, (38) tetrahidronaftil skupine, (39) dihidrokinazolinil skupine, (40) benzoksazolil skupine, (41) tiazolil skupine, (42) kinazolinil skupine, (43) ftalazinil skupine, (44) pirazinil skupine i (45) kromenil skupine, pri čemu takve aromatske ili heterocikličke skupine mogu imati jedan ili više supstituenata odabrana od (1-1) atoma halogena, (1-2) C1-C6 alkilne skupine, (1-3) C1-C6 alkanoil skupine, (1-4) halogen-supstituirane C1-C6 alkilne skupine, (1-5) halogen-supstituirane C1-C6 alkoksi skupine, (1-6) cijano skupine, (1-7) C1-C6 alkoksi skupine, (1-8) C1-C6 alkiltio skupine, (1-9) imidazolil skupine, (1-10) tri- C1-C6 alkilsilil skupine, (1-11) oksadiazolil skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-12) pirolidinil skupine koja može imati okso skupinu (skupine), (1-13) fenil skupine koja može imati C1-C6 alkoksi skupinu (skupine), (1-14) C1-C6 alkilamino- C1-C6 alkilne skupine, (1-15) okso skupine, (1-16) pirazolil skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-17) tienil skupine, (1-18) furil skupine, (1-19) tiazolil skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-20) C1-C6 alkilamino skupine, (1-21) pirimidil skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-22) fenil-C2-C6 alkenilne skupine, (1-23) fenoksi skupine koja može imati atom (atome) halogena, (1-24) fenoksi- C1-C6 alkilne skupine, (1-25) pirolidinil- C1-C6 alkoksi skupine, (1-26) C1-C6 alkilsulfamoil skupine, (1-27) piridaziniloksi skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-28) fenil- C1-C6 alkilne skupine, (1-29) C1-C6 alkilamino- C1-C6 alkoksi skupine, (1-30) imidazolil- C1-C6 alkilne skupine, (1-31) fenil- C1-C6 alkoksi skupine, (1-32) hidroksi skupine, (1-33) C1-C6 alkoksikarbonilne skupine, (1-34) hidroksi- C1-C6 alkilne skupine, (1-35) oksazolil skupine, (1-36) piperidil skupine, (1-37) pirolil skupine, (1-38) morfolinil- C1-C6 alkilne skupine, (1-39) piperazinil- C1-C6 alkilne skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-40) piperidil- C1-C6 alkilne skupine, (1-41) pirolidinil- C1-C6 alkilne skupine, (1-42) morfolinil skupine, i (1-43) piperazinil skupine koja može imati C1-C6 alkilnu skupinu (skupine).
2. Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da R4 predstavlja bilo koju od (1) fenilne skupine, (2) indolil skupine, (3) benzotienil skupine, (4) naftil skupine, (5) benzofuril skupine, (6) kinolil skupine, (7) izokinolil skupine, (8) piridil skupine, (9) tienil skupine, (10) dihidrobenzoksazinil skupine, (11) dihidrobenzodioksinil skupine, (12) dihidrokinolil skupine, (13) kromanil skupine, (14) kinoksalinil skupine, (15) dihidroindenil skupine, (16) dihidrobenzofuril skupine, (17) benzodioksolil skupine, (18) indazolil skupine, (19) benzotiazolil skupine, (20) indolinil skupine, (21) tienopiridilil skupine, (22) tetrahidrobenzazepinil skupine, (23) tetrahidrobenzodiazepinil skupine, (24) dihidrobenzodioksepinil skupine, (25) fluorenil skupine, (26) piridazinil skupine, (27) tetrahidrokinolil skupine, (28) karbazolil skupine, (29) fenantril skupine, (30) dihidroacenaftilenil skupine, (31) pirolopiridil skupine, (32) antril skupine, (33) benzodioksinil skupine, (34) pirolidinil skupine, (35) pirazolil skupine, (36) oksadiazolil skupine, (37) pirimidinil skupine, (38) tetrahidronaftil skupine, (39) dihidrokinazolinil skupine, (40) benzoksazolil skupine, (41) tiazolil skupine, (42) kinazolinil skupine, (43) ftalazinil skupine, (44) pirazinil skupine, i (45) kromenil skupine, gdje takve aromatske ili heterocikličke skupine mogu imati 1 do 4 supstituenta odabrana od (1-1) atoma halogena, (1-2) C1-C6 alkilne skupine, (1-3) C1-C6 alkanoilne skupine, (1-4) halogen-supstituirane C1-C6 alkilne skupine, (1-5) halogen-supstituirane C1-C6 alkoksi skupine, (1-6) cijano skupine, (1-7) C1-C6 alkoksi skupine, (1-8) C1-C6 alkiltio skupine, (1-9) imidazolil skupine, (1-10) tri- C1-C6 alkilsilil skupine, (1-11) oksadiazolil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-12) pirolidinil skupine koji može imati 1 okso skupinu, (1-13) fenilne skupine koja može imati 1 C1-C6 alkoksi skupinu, (1-14) C1-C6 alkilamino- C1-C6 alkilnu skupinu, (1-15) okso skupine, (1-16) pirazolil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-17) tienilne skupine, (1-18) furilne skupine, (1-19) tiazolil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-20) C1-C6 alkilamino skupine, (1-21) pirimidil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-22) fenil-C2-C6 alkenilne skupine, (1-23) fenoksi skupine koja može imati 1 atom halogena, (1-24) fenoksi- C1-C6 alkilne skupine, (1-25) pirolidinil- C1-C6 alkoksi skupine, (1-26) C1-C6 alkilsulfamoil skupine, (1-27) piridaziniloksi skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-28) fenil- C1-C6 alkilne skupine, (1-29) C1-C6 alkilamino- C1-C6 alkoksi skupine, (1-30) imidazolil- C1-C6 alkilne skupine, (1-31) fenil- C1-C6 alkoksi skupine, (1-32) hidroksi skupine, (1-33) C1-C6 alkoksikarbonilne skupine, (1-34) hidroksi- C1-C6 alkilne skupine, (1-35) oksazolil skupine, (1-36) piperidil skupine, (1-37) pirolil skupine, (1-38) morfolinil- C1-C6 alkilne skupine, (1-39) piperazinil- C1-C6 alkilne skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-40) piperidil- C1-C6 alkilne skupine, (1-41) pirolidinil- C1-C6 alkilne skupine, (1-42) morfolinil skupine, i (1-43) piperazinil skupine koja može imati 1 C1-C6 alkilnu skupinu.
3. Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 2, naznačen time, da R1 predstavlja vodik, C1-C6 alkilnu skupinu, hidroksi- C1-C6 alkilnu skupinu, benzilnu skupinu ili tri- C1-C6 alkilsililoksi- C1-C6 alkilnu skupinu; i R4 predstavlja bilo koju od (1) feniline skupine, (2) indolil skupine, (4) naftil skupine, (5) benzofuril skupine, i (31) pirolopiridil skupine, pri čemu takve aromatske ili heterocikličke skupine mogu imati 1 do 4 supstituenta odabrana od (1-1) atoma halogena, (1-2) C1-C6 alkilne skupine, (1-3) C1-C6 alkanoil skupine, (1-4) halogen-supstituirane C1-C6 alkilne skupine, (1-5) halogen-supstituirane C1-C6 alkoksi skupine, (1-6) cijano skupine, (1-7) C1-C6 alkoksi skupine, (1-8 C1-C6 alkilthio skupine, (1-9) imidazolil skupine, (1-10) tri- C1-C6 alkilsilil skupine, (1-11) oksadiazolil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-12) pirolidinil skupine koja može imati 1 okso skupinu, (1-13) fenilne skupine koja može imati 1 C1-C6 alkoksi skupinu, (1-14) C1-C6 alkilamino- C1-C6 alkilnu skupine, (1-15) okso skupine, (1-16) pirazolil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-17) tienil skupine, (1-18) furil skupine, (1-19) tiazolil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-20) C1-C6 alkilamino skupine, (1-21) pirimidil skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-22) fenil- C2-C6 alkenilne skupine, (1-23) fenoksi skupine which may have 1 halogen atom, (1-24) fenoksi- C1-C6 alkilne skupine, (1-25) pirolidinil- C1-C6 alkoksi skupine, (1-26) C1-C6 alkilsulfamoil skupine, (1-27) piridaziniloksi skupine koja može imati 1 C1-C6 alkilnu skupinu, (1-28) fenil- C1-C6 alkilne skupine, (1-29) C1-C6 alkilamino- C1-C6 alkoksi skupine, (1-30) imidazolil- C1-C6 alkilne skupine, (1-31) fenil- C1-C6 alkoksi skupine, (1-32) hidroksi skupine, (1-34) hidroksi- C1-C6 alkilne skupine, (1-35) oksazolil skupine, (1-36) piperidil skupine, (1-37) pirolil skupine, (1-38) morfolinil- C1-C6 alkilne skupine, (1-39) piperazinil- C1-C6 alkilne skupine koja može imati C1-C6 alkilnu skupinu (skupine), (1-40) piperidil- C1-C6 alkilne skupine, (1-41) pirolidinil- C1-C6 alkilne skupine, (1-42) morfolinil skupine, i (1-43) piperazinil skupine koja može imati 1 C1-C6 alkilnu skupinu.
4. Spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 3, naznačen time, da R1 predstavlja vodik; R2 i R3, koji su isti ili različiti, svaki neovisno predstavlja C1-C6 alkilnu skupinu; ili R2 i R3 su vezani tako da tvore ciklo- C3-C8 alkilnu skupinu; i R4 predstavlja bilo koji od (1) fenilne skupine, (2) indolil skupine, (4) naftil skupine, (5) benzofuril skupine, i (31) pirolopiridil skupine, pri čemu takve aromatske ili heterocikličke skuppine mogu imati 1 do 2 supstituenta odabrana od (1-1) atoma halogena, (1-2) C1-C6 alkil skupine, (1-5) halogen-substituted C1-C6 alkoksi skupine, (1-6) cijano skupine, i (1-7) C1-C6 alkoksi skupine.
5. Heterociklički spoj, naznačen time, da je predstavljen općom formulom (1) ili njegova sol u skladu s patentnim zahtjevom 4, koji je odabran od (4aS,8aR)-1-(4-klorofenil)-3,3-dimetildekahidrokinoksalina, 2-kloro-4-((4aS,8aS)-3,3-dimetiloktahidrokinoksalin-1(2H)-il)benzonitrila, (4aS,8aR)-1-(3-kloro-4-fluorofenil)-3,3-dimetildekahidrokinoksalina, (4aS,8aR)-1-(7-fluorobenzofuran-4-il)-3,3-dimetildekahidrokinoksalina, 5-((4aR,8aS)-3,3-dimetiloktahidrokinoksalin-1(2H)-il)-1-metil-1H-indol-2-karbonitrila, (4a’R,8a,S)-4,-(7-metoksibenzofuran-4-il)oktahidro-1,H-spiro[ciklobutan-1,2’-kinoksaline], (4aS,8aR)-1-(6,7-difluorobenzofuran-4-il)-3,3-dimetildekahidrokinoksalina, 5-((4aS,8aS)-3,3-dimetiloktahidrokinoksalin-1(2H)-il)-1H-indol-2-karbonitrila, 6-((4aS,8aS)-3,3-dimetiloktahidrokinoksalin-1(2H)-il)-2-naftonitrila, (4aS,8aS)-3,3-dimetil-1-(1H-pirolo[2,3-b]piridin-4-il)dekahidrokinoksalina, (4aS,8aS)-1-(4-(difluorometoksi)-3-fluorofenil)-3,3-dimetildekahidrokinoksalina, (4aS,8aS)-1-(4-difluorometoksi)fenil-3,3-dimetildekahidrokinoksalina i (4aR,8aR)-1-(4-difluorometoksi)-3-fluorofenil-3,3-dimetildekahidrokinoksalina.
6. Farmaceutski pripravak koji sadrži spoj predstavljen formulom (1) ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da je djelatni sastojak i farmaceutski prihvatljiv nosač.
7. Spoj formule (1) ili njegova farmaceutski prihvatljiva sol kako je definirano u patentnom zahtjevu 1, naznačen time, da se koristi u liječenju bolesti uzrokovanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina, pri čemu je bolest odabrana iz skupine koja se sastoji od depresije, depresivnog stanja uzrokovanog poremećajem prilagodbe, anksioznosti izazvane poremećajem prilagodbe, anksioznosti izazvane raznim poremećajima, općeg poremećaja anksioznosti, fobije, opsesivno-kompulzivnog poremećaja, poremećaja panike, posttraumatskog stresnog poremećaja, akutnog stresnog poremećaja, hipohondrije, disocijativne amnezije, poremećaja osobnosti, tjelesnog dismorfnog poremećaja, poremećaja jedenja, pretilosti, kemijske ovisnosti, boli, fibromijalgije, Alzheimer-ove bolesti, gubitka pamćenja, Parkinsonove bolesti, sindroma nemirnih nogu, endokrinog poremećaja, vazospazma, cerebralne ataksije, gastrointestinalnog poremećaja, negativnog sindroma schizofrenije, predmenstrualnog sindroma, urinarne inkontinencije izazvane stresom, Tourett-ovog poremećaja, hiperaktivnog poremećaja pažnje (ADHD), autizma, Aspergerovog sindroma, poremećaja kontrole nagona, trihotilomanije, kleptomanije, poremećaja kockanja, Cluster glavobolje, migrene, kronične paroksizmalne migrene, sindorma kroničnog umora, preuranjene ejakulacije, muške impotencije, narkolepsije, primarne hipersomnije, katapleksije, sindroma apneje u snu i glavobolje.
8. Spoj za uporabu u skladu s patentnim zahtjevom 7, naznačen time, da je depresija odabrana iz skupine koja se sastoji od glavnih poremećaja depresije; bipolarnog poremećaja tip I; bipolarnog poremećaja tip II; mješovitih stanja; distimičnog poremećaja; čestih epozioda bipolarnog poremećaja (rapid cycler); netipične depresije; sezonskog afektivnog poremećaja; postporođajne depresije; hipomelankolije; rekurentnog kratkog depresivnog poremećaja; refraktorne depresije; kronične depresije; dvostruke depresije; poremećaja raspoloženja uzrokovanog alkoholom; pomiješanog anksiozno-depresivnog poremećaja; depresije izazvane različitim fizičkim poremećajima poput primjerice Cushing-ovog sindroma, hipotiroidizma, hiperparatiroidizma, Addison-ove bolesti, amenorea-galaktorea sindroma, Parkinson-ove bolesti, Alzheimer-ove bolesti, cerebrovaskularne demencije, moždanog udara, krvarenja u mozgu, subarahnoidnog krvarenja, šećerne bolesti, virusne infekcije, multipla skleroze, sindroma kroničnog umora, bolesti srčane arterije, boli, raka, itd.; presenilnu depresije; senilna depresije; depresije u djece i adolescenata; depresija izazvane lijekovima kao što je interferon, itd.
9. Spoj za uporabu u skladu s patentnim zahtjevom 7, naznačen time, da je anksioznost uzrokovana raznim poremećajima koji su odabrani od skupine koja se sastoji od anksioznosti izazvane ozljedom glave, infekcije mozga, pogoršanog stanja unutarnjeg uha, srčanog zatajenja, aritmije, hiperadrenalizma, hipertiroidizma, astme i kronične opstruktivne plućne bolesti.
10. Spoj za uporabu u skladu s patentnim zahtjevom 7, naznačen time, da je bol odabrana iz skupine koja se sastoji od kronične boli, psihogene boli, neuropatske boli, boli fantomskog uda, posterpijske neuralgije, sindroma vratne kralježnice, boli kod ozljede leđne moždine, trigeminalne neuralgije, dijabetičke neuropatije.
11. Postupak za proizvodnju spoja opće formule (1): [image] ili njegove farmaceutski prihvatljive soli, pri čemu su m, l, n, X, R1, R2 i R3 definirani u gore navedenom patentnom zahtjevu 1, naznačen time, da se postupak sastoji od reagiranja spoja predstavljenog općom formulom; [image] gdje su m, l, n, X, R1, R2 i R3 definirani u gornjem patentnom zahtjevu 1 i spoja predstavljenog općom formulom; R4-X1 gdje su R4 i X1 definirani u gore navedenom patentnom zahtjevu 1.
HRP20151282TT 2010-09-13 2015-11-26 Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina HRP20151282T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010204747 2010-09-13
PCT/JP2011/071174 WO2012036253A1 (en) 2010-09-13 2011-09-12 Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.
EP11764005.2A EP2616460B1 (en) 2010-09-13 2011-09-12 Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine.

Publications (1)

Publication Number Publication Date
HRP20151282T1 true HRP20151282T1 (hr) 2016-01-01

Family

ID=44721008

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151282TT HRP20151282T1 (hr) 2010-09-13 2015-11-26 Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina

Country Status (29)

Country Link
US (5) US9090572B2 (hr)
EP (1) EP2616460B1 (hr)
JP (1) JP5973994B2 (hr)
KR (1) KR101944552B1 (hr)
CN (1) CN103180312B (hr)
AR (1) AR082962A1 (hr)
AU (1) AU2011303009B2 (hr)
BR (1) BR112013005823B8 (hr)
CA (1) CA2811080C (hr)
CO (1) CO6680697A2 (hr)
CY (1) CY1117026T1 (hr)
DK (1) DK2616460T3 (hr)
EA (1) EA024099B1 (hr)
ES (1) ES2553387T3 (hr)
HK (1) HK1185878A1 (hr)
HR (1) HRP20151282T1 (hr)
HU (1) HUE025873T2 (hr)
IL (1) IL225105A (hr)
MX (1) MX2013002530A (hr)
MY (1) MY164789A (hr)
NZ (1) NZ608117A (hr)
PL (1) PL2616460T3 (hr)
PT (1) PT2616460E (hr)
SG (1) SG188402A1 (hr)
SI (1) SI2616460T1 (hr)
TW (1) TWI526434B (hr)
UA (1) UA111950C2 (hr)
WO (1) WO2012036253A1 (hr)
ZA (1) ZA201301718B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013137479A1 (en) * 2012-03-12 2013-09-19 Otsuka Pharmaceutical Co., Ltd. Decahydroquinoxaline derivatives and analogs thereof
CN104364236B (zh) * 2012-05-09 2018-01-16 拜尔农作物科学股份公司 5‑卤代吡唑二氢茚基甲酰胺
CN105143227A (zh) 2013-02-20 2015-12-09 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物
AU2018351559B2 (en) 2017-10-19 2023-11-16 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds, compositions comprising heterocyclic compound, and methods of use thereof
CN117616013A (zh) * 2021-07-13 2024-02-27 大塚制药株式会社 氢化喹喔啉
CN116554127A (zh) * 2022-01-28 2023-08-08 成都麻沸散医药科技有限公司 哌嗪取代苯酚类衍生物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU390391A1 (ru) 1971-04-12 1973-07-11 УСТРОЙСТВО дл ИЗМЕРЕНИЯ ДАВЛЕНИЯ
SU390091A1 (ru) * 1971-07-12 1973-07-11 С. И. Бурмистров, Н. В. Макаревич , Л. Я. Кравченко Днепропетровский химико технологический институт Дзержинского Способ получения 1-аренсульфонил-4- -арилдекагидрохиноксалинов
DE4210941A1 (de) 1992-04-02 1993-10-07 Bayer Ag Neue 9-Fluor-7.oxo-7H-pyrido[1,2,3-d,e][1,4]benzoxacin-6-carbonsäuren und -ester
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
EP0876358A1 (en) * 1996-01-05 1998-11-11 Novartis AG Herbicidal 1,2,4,6-thiatriazines
ATE273970T1 (de) * 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
IT1312310B1 (it) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
PE20040804A1 (es) * 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
MX2009001494A (es) * 2006-08-07 2009-04-23 Albany Molecular Res Inc 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
US20100292205A1 (en) * 2006-08-23 2010-11-18 Pfizer Inc. Pyrimidone Compounds As GSK-3 Inhibitors
UA108596C2 (xx) * 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
EP2437600A4 (en) * 2009-06-03 2012-11-07 Glaxosmithkline Llc BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
TWM369750U (en) 2009-06-03 2009-12-01 Yu-Hao Shen Self-rotation mop structure
WO2011068171A1 (ja) * 2009-12-03 2011-06-09 第一三共株式会社 二環性含窒素飽和へテロ環誘導体

Also Published As

Publication number Publication date
KR20130115221A (ko) 2013-10-21
CY1117026T1 (el) 2017-04-05
PL2616460T3 (pl) 2016-03-31
BR112013005823A2 (pt) 2016-09-20
KR101944552B1 (ko) 2019-01-31
MY164789A (en) 2018-01-30
US20130261081A1 (en) 2013-10-03
HUE025873T2 (en) 2016-05-30
AU2011303009A1 (en) 2013-03-28
CN103180312B (zh) 2016-01-20
US20160058757A1 (en) 2016-03-03
US10064879B2 (en) 2018-09-04
WO2012036253A1 (en) 2012-03-22
SG188402A1 (en) 2013-04-30
US9090572B2 (en) 2015-07-28
BR112013005823B1 (pt) 2021-09-08
EA024099B1 (ru) 2016-08-31
NZ608117A (en) 2014-12-24
TW201240973A (en) 2012-10-16
AR082962A1 (es) 2013-01-23
TWI526434B (zh) 2016-03-21
MX2013002530A (es) 2013-03-22
DK2616460T3 (en) 2016-01-18
EA201390374A1 (ru) 2013-08-30
US10603331B2 (en) 2020-03-31
SI2616460T1 (sl) 2016-03-31
ES2553387T3 (es) 2015-12-09
US20170224713A1 (en) 2017-08-10
US11273168B2 (en) 2022-03-15
UA111950C2 (uk) 2016-07-11
EP2616460A1 (en) 2013-07-24
PT2616460E (pt) 2015-11-24
ZA201301718B (en) 2014-05-28
CA2811080C (en) 2019-03-26
US20200281951A1 (en) 2020-09-10
JP5973994B2 (ja) 2016-08-23
US20190142852A1 (en) 2019-05-16
CO6680697A2 (es) 2013-05-31
AU2011303009B2 (en) 2016-01-21
BR112013005823B8 (pt) 2022-11-22
HK1185878A1 (zh) 2014-02-28
IL225105A (en) 2016-12-29
EP2616460B1 (en) 2015-10-28
CA2811080A1 (en) 2012-03-22
JP2013537875A (ja) 2013-10-07
CN103180312A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
HRP20151282T1 (hr) Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina
AU2010339423B2 (en) Therapeutic compounds and related methods of use
TWI355383B (en) Process for the manufacture of dihydropteridinones
CN102869256B (zh) 儿茶酚o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
RU2468025C2 (ru) Терапевтические агенты
RU2270194C2 (ru) Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения
DK1622880T6 (da) Substituerede dihydroquinazoliner med antivirale egenskaber
HRP20151077T1 (hr) Derivati pirazola
AU2020302338A1 (en) 2,3-dihydroquinazolin compounds as NAV1.8 inhibitors
CA2564994A1 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
CN102858177B (zh) 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
US20090306169A1 (en) Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors
CA2702482A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
TW200914431A (en) Novel morpholine compounds
JP6804469B2 (ja) ベンゾイミダゾロン及びベンゾチアゾロン化合物並びにａｍｐａ受容体調節因子としてのそれらの使用
CA2543710A1 (en) Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
US20130137707A1 (en) Pyrazolopyrimidine pde 10 inhibitors
EP1987007A1 (en) 3-aminopyrazolines for treatment of neurodegenerative and psychiatric diseases
CN103096893A (zh) 甘氨酸转运体-1抑制剂、其制备方法及其用途
JP6389933B2 (ja) Ｇｐｒ６モジュレーターとしてのキノキサリン誘導体
TWI429631B (zh) 甘胺酸轉運體-１抑制劑
MX354410B (es) Derivados de benzamida sustituida.
JP2020511515A5 (hr)
NZ580802A (en) Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP3087060B1 (en) Pyrimidone carboxamide compounds as pde2 inhibitors